Legal notices

Company identification

Aeviant Biosciences Inc. is a private, independent biosciences company incorporated in British Columbia, Canada on April 24, 2026, and based in British Columbia, Canada. General and legal inquiries may be directed to [email protected].

This website does not publish a residential address. Any formal notice that requires a particular delivery method or registered address should be coordinated with Aeviant in advance.

Investigational status

AVX-1 is a computational, discovery-stage research program. It has not been experimentally validated, tested in humans, or evaluated or approved by Health Canada, the U.S. Food and Drug Administration, or any other regulator. It is not available for clinical use, and safety and efficacy have not been established.

Nothing on this website is an offer to provide access to an investigational product or an invitation to participate in a clinical study.

Scientific content and evidence status

Scientific content is provided for corporate and scientific information and is not medical advice. Aeviant distinguishes established biology, preclinical evidence, Aeviant interpretation and program objectives.

References to an intended mechanism, target profile, advancement criterion or potential future value describe a research objective or hypothesis unless the relevant page expressly identifies supporting evidence. Computational analyses support target characterization, hypothesis generation and prioritization; they are not experimental proof.

Forward-looking information

This website may include conditional statements about research objectives, development plans, potential mechanisms, future programs, collaborations or possible therapeutic value. Such statements reflect current expectations and are subject to scientific, technical, financing, intellectual-property, regulatory and other risks.

Forward-looking statements are not promises of outcome. Aeviant may revise, redirect or terminate work as evidence changes and does not undertake to update every statement except where required by applicable law.

Intellectual property notices

The Aeviant name, wordmark, original website content and visual materials are owned by or licensed to Aeviant Biosciences Inc. unless otherwise identified. Third-party names, publications, figures and marks remain the property of their respective owners.

Patent pending. Nothing on this website grants a licence or constitutes an offer concerning Aeviant intellectual property.

Confidentiality

Public pages include only program information approved for disclosure. Technical discussion beyond the information published here requires a signed non-disclosure agreement.

Contacting Aeviant through this website or by email does not create a confidential relationship. Do not send unpublished mechanisms, structures, chemical information, research results or other confidential material before an appropriate agreement is in place.

No offering or investment advice

Website content does not constitute an offer to sell or a solicitation to buy securities, nor does it constitute investment, financial, legal or tax advice. Any investment or partnering process is subject to separate diligence, documentation and applicable requirements.

Corrections and questions

Aeviant aims to correct material inaccuracies and update public scientific claims as evidence develops. Questions about a statement, source, attribution or legal notice may be sent to the company contact below.